Aytu BioPharma Files 8-K with Corporate Updates
Ticker: AYTU · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1385818
| Field | Detail |
|---|---|
| Company | Aytu Biopharma, Inc (AYTU) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: AYTU
TL;DR
AYTU filed an 8-K on Oct 1st, updating corporate info & former names. No major news, just housekeeping.
AI Summary
Aytu BioPharma, Inc. filed an 8-K on October 1, 2024, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 7900 East Union Avenue, Suite 920, Denver, CO 80237. The company was formerly known as Aytu Bioscience, Inc. and Rosewind Corp.
Why It Matters
This filing provides essential corporate information and disclosures, including changes in company name and address, which are important for investors to track the company's official status and operational details.
Risk Assessment
Risk Level: low — This filing is primarily administrative and does not contain significant financial or operational news that would immediately impact the company's risk profile.
Key Players & Entities
- AYTU BIOPHARMA, INC (company) — Registrant
- 0001385818 (company) — Central Index Key
- 7900 East Union Avenue, Suite 920, Denver, CO 80237 (company) — Principal executive offices
- AYTU BIOSCIENCE, INC (company) — Former company name
- Rosewind CORP (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as well as to update corporate information.
When was this 8-K filing submitted?
This 8-K filing was submitted on October 1, 2024.
What is the current principal executive office address for Aytu BioPharma, Inc.?
The principal executive offices are located at 7900 East Union Avenue, Suite 920, Denver, CO 80237.
What were some of Aytu BioPharma's former company names?
Aytu BioPharma, Inc. was formerly known as Aytu Bioscience, Inc. and Rosewind Corp.
What is the company's fiscal year end?
The company's fiscal year ends on June 30.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-10-01 08:00:14
Key Financial Figures
- $0.0001 — ch Registered Common Stock , par value $0.0001 per share AYTU The Nasdaq Capital M
Filing Documents
- aytu20240723_8k.htm (8-K) — 25KB
- ex_702328.htm (EX-99.1) — 13KB
- logo01.jpg (GRAPHIC) — 4KB
- logo.jpg (GRAPHIC) — 4KB
- 0001437749-24-030297.txt ( ) — 191KB
- aytu-20241001.xsd (EX-101.SCH) — 3KB
- aytu-20241001_def.xml (EX-101.DEF) — 12KB
- aytu-20241001_lab.xml (EX-101.LAB) — 15KB
- aytu-20241001_pre.xml (EX-101.PRE) — 12KB
- aytu20240723_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 1, 2024, Aytu issued a press release titled "Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 99.1 Press Release dated October 1, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AYTU BIOPHARMA, INC. Date: October 1, 2024 By: /s/ Mark K. Oki Mark K. Oki Chief Financial Officer